000504 *ST生物
已收盘 05-06 15:00:00
资讯
新帖
简况
图解南华生物一季报：第一季度单季净利润同比增19.92%
证券之星 · 04-28
图解南华生物一季报：第一季度单季净利润同比增19.92%
4月28日南华生物（000504）龙虎榜数据：游资呼家楼上榜
证券之星 · 04-28
4月28日南华生物（000504）龙虎榜数据：游资呼家楼上榜
南华生物：在《2024年年度报告》披露后，公司不会退市，但可能被实施退市风险警示
证券之星 · 04-25
南华生物：在《2024年年度报告》披露后，公司不会退市，但可能被实施退市风险警示
南华生物：公司2024年度净利润、扣除非经常性损益后的净利润均为负值且扣除后营业收入低于3亿元
证券之星 · 04-25
南华生物：公司2024年度净利润、扣除非经常性损益后的净利润均为负值且扣除后营业收入低于3亿元
4月24日南华生物（000504）龙虎榜数据：游资宁波桑田路上榜
证券之星 · 04-24
4月24日南华生物（000504）龙虎榜数据：游资宁波桑田路上榜
4月23日南华生物（000504）龙虎榜数据：游资呼家楼上榜
证券之星 · 04-23
4月23日南华生物（000504）龙虎榜数据：游资呼家楼上榜
南华生物4月23日现3笔大宗交易 成交金额970.9万元
新浪证券-红岸工作室 · 04-23
南华生物4月23日现3笔大宗交易 成交金额970.9万元
南华生物或被实施退市风险警示（*ST）
市场资讯 · 04-21
南华生物或被实施退市风险警示（*ST）
南华生物(000504.SZ)：公司股票交易可能被实施退市风险警示
智通财经 · 04-21
南华生物(000504.SZ)：公司股票交易可能被实施退市风险警示
南华生物最新公告：修正2024年度业绩预告 公司股票可能被实施退市风险警示
证券之星 · 04-21
南华生物最新公告：修正2024年度业绩预告 公司股票可能被实施退市风险警示
南华生物：修正2024年度业绩预告 公司股票可能被实施退市风险警示
美港电讯 · 04-21
南华生物：修正2024年度业绩预告 公司股票可能被实施退市风险警示
南华生物（000504）1月23日主力资金净卖出286.86万元
证券之星 · 01-23
南华生物（000504）1月23日主力资金净卖出286.86万元
南华生物(000504.SZ)发预盈，预计2024年度净利润1250万元–1550万元 同比扭亏为盈
智通财经 · 01-21
南华生物(000504.SZ)发预盈，预计2024年度净利润1250万元–1550万元 同比扭亏为盈
南华生物：预计2024年全年每股收益盈利:0.039元至0.049元
证券之星 · 01-21
南华生物：预计2024年全年每股收益盈利:0.039元至0.049元
异动快报：南华生物（000504）1月14日9点39分触及涨停板
证券之星 · 01-14
异动快报：南华生物（000504）1月14日9点39分触及涨停板
我国首款干细胞治疗药品上市！概念股名单一览
21世纪经济报道 · 01-03
我国首款干细胞治疗药品上市！概念股名单一览
我国首款干细胞治疗药品上市！多家上市公司回应
美港电讯 · 01-03
我国首款干细胞治疗药品上市！多家上市公司回应
我国首款干细胞治疗药品上市！多家上市公司回应
21世纪经济报道 · 01-03
我国首款干细胞治疗药品上市！多家上市公司回应
A股细胞免疫治疗概念股高开，中源协和涨超7%，冠昊生物涨超5%，南华生物、开能健康、阳普医疗等高开。
美港电讯 · 01-03
A股细胞免疫治疗概念股高开，中源协和涨超7%，冠昊生物涨超5%，南华生物、开能健康、阳普医疗等高开。
加载更多
公司概况
公司名称：
南华生物医药股份有限公司
所属行业：
科技推广和应用服务业
上市日期：
1992-12-08
主营业务：
南华生物医药股份有限公司主要从事“生物医药”和“节能环保”两个板块的业务。公司“生物医药”板块业务包括干细胞和免疫细胞的分离、培养、储存服务及其下游产品和临床应用的研究；公司“节能环保”板块业务包括节能工程及产品研发销售、特种行业污水综合治理、分布式能源站投资经营、综合节能项目投资运营等。
发行价格：
1.00
{"stockData":{"symbol":"000504","market":"SZ","secType":"STK","nameCN":"*ST生物","latestPrice":6,"timestamp":1746515001000,"preClose":5.71,"halted":0,"volume":9254375,"delay":0,"changeRate":0.0508,"floatShares":311000000,"shares":330000000,"eps":-0.0585,"marketStatus":"已收盘","change":0.29,"latestTime":"05-06 15:00:00","open":5.77,"high":6,"low":5.76,"amount":54786600,"amplitude":0.042,"askPrice":0,"askSize":0,"bidPrice":6,"bidSize":7703,"shortable":0,"etf":0,"ttmEps":-0.0585,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746581400000},"marketStatusCode":5,"adr":0,"adjPreClose":5.71,"symbolType":"stock","openAndCloseTimeList":[[1746495000000,1746502200000],[1746507600000,1746514800000]],"highLimit":6,"lowLimit":5.42,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":330023098,"isCdr":false,"pbRate":8.02,"roa":"--","roe":"--","epsLYR":-0.06,"committee":0,"marketValue":1980000000,"turnoverRate":0.0298,"status":0,"floatMarketCap":1864000000},"requestUrl":"/m/hq/s/000504","defaultTab":"news","newsList":[{"id":"2531264832","title":"图解南华生物一季报：第一季度单季净利润同比增19.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531264832","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531264832?lang=zh_cn&edition=full","pubTime":"2025-04-29 05:10","pubTimestamp":1745874609,"startTime":"0","endTime":"0","summary":"证券之星消息，南华生物2025年一季报显示，公司主营收入2245.36万元，同比下降13.55%；归母净利润-221.86万元，同比上升19.92%；扣非净利润-345.69万元，同比上升9.77%；负债率54.27%，投资收益157.83万元，财务费用0.72万元，毛利率64.96%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042900002465.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000504"],"gpt_icon":0},{"id":"2530342466","title":"4月28日南华生物（000504）龙虎榜数据：游资呼家楼上榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2530342466","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530342466?lang=zh_cn&edition=full","pubTime":"2025-04-28 17:24","pubTimestamp":1745832249,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2025年4月28日公布的交易公开信息显示，南华生物因连续三个交易日内，跌幅偏离值累计达到20%的证券登上龙虎榜。此次是近5个交易日内第3次上榜。截至2025年4月28日收盘，南华生物报收于5.72元，下跌4.03%，换手率6.93%，成交量21.52万手，成交额1.22亿元。从龙虎榜公布的三日买卖数据来看，机构合计净买入303.65万元。呼家楼等知名游资榜上有名。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042800026983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0086","000504","BK0042","BK0282"],"gpt_icon":0},{"id":"2530133839","title":"南华生物：在《2024年年度报告》披露后，公司不会退市，但可能被实施退市风险警示","url":"https://stock-news.laohu8.com/highlight/detail?id=2530133839","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530133839?lang=zh_cn&edition=full","pubTime":"2025-04-25 20:54","pubTimestamp":1745585640,"startTime":"0","endTime":"0","summary":"证券之星消息，南华生物(000504)04月25日在投资者关系平台上答复投资者关心的问题。投资者提问：请问年报后公司会退市吗？南华生物回复：尊敬的投资者，您好。在《2024年年度报告》披露后，公司不会退市，但可能被实施退市风险警示。公司上下将在各大股东支持下，攻坚克难，努力经营，争取在2025年取得良好成绩，早日解除退市风险警示。有关公司信息敬请以公司在指定媒体披露的信息为准，并注意投资风险，感谢关注！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042500034624.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0086","000504","BK0282","BK0042","BK0046"],"gpt_icon":0},{"id":"2530138025","title":"南华生物：公司2024年度净利润、扣除非经常性损益后的净利润均为负值且扣除后营业收入低于3亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530138025","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530138025?lang=zh_cn&edition=full","pubTime":"2025-04-25 20:53","pubTimestamp":1745585635,"startTime":"0","endTime":"0","summary":"证券之星消息，南华生物04月25日在投资者关系平台上答复投资者关心的问题。根据公司2025年4月22日对外披露的预告，预计公司 2024 年度净利润、扣除非经常性损益后的净利润均为负值且扣除后营业收入低于3 亿元，触及《深圳证券交易所股票上市规则》第 9.3.1 条第（一）项规定，在《2024年年度报告》披露后，公司股票交易可能被实施退市风险警示，但不属于退市情形。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042500034621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000504"],"gpt_icon":0},{"id":"2529672250","title":"4月24日南华生物（000504）龙虎榜数据：游资宁波桑田路上榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2529672250","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529672250?lang=zh_cn&edition=full","pubTime":"2025-04-24 17:30","pubTimestamp":1745487004,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2025年4月24日公布的交易公开信息显示，南华生物因日跌幅偏离值达到7%的前5只证券登上龙虎榜。此次是近5个交易日内第2次上榜。截至2025年4月24日收盘，南华生物报收于6.57元，下跌10.0%，已连续跌停3天，换手率3.32%，成交量10.33万手，成交额6784.38万元。从龙虎榜公布的当日买卖数据来看，宁波桑田路等知名游资榜上有名。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042400029837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000504","BK0282","BK0086","BK0042","BK0046"],"gpt_icon":0},{"id":"2529575542","title":"4月23日南华生物（000504）龙虎榜数据：游资呼家楼上榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2529575542","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529575542?lang=zh_cn&edition=full","pubTime":"2025-04-23 17:41","pubTimestamp":1745401265,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2025年4月23日公布的交易公开信息显示，南华生物因连续三个交易日内，跌幅偏离值累计达到20%的证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2025年4月23日收盘，南华生物报收于7.3元，下跌9.99%，已连续跌停2天，换手率0.45%，成交量1.39万手，成交额1017.91万元。从龙虎榜公布的三日买卖数据来看，机构合计净买入34.09万元。呼家楼等知名游资榜上有名。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042300030731.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0086","BK0282","000504","BK0046"],"gpt_icon":0},{"id":"2529147575","title":"南华生物4月23日现3笔大宗交易 成交金额970.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529147575","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529147575?lang=zh_cn&edition=full","pubTime":"2025-04-23 17:40","pubTimestamp":1745401200,"startTime":"0","endTime":"0","summary":" 4月23日，南华生物（维权）收跌9.99%，收盘价为7.30元，发生3笔大宗交易，合计成交量133万股，成交金额970.9万元。 进一步统计，近3个月内该股累计发生3笔大宗交易，合计成交金额为970.9万元。该股近5个交易日累计下跌20.22%，主力资金合计净流出1717.82万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2025-04-23/doc-ineucyiq6730716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000504","BK0042","BK0282","BK0086","BK0046"],"gpt_icon":0},{"id":"2529801578","title":"南华生物或被实施退市风险警示（*ST）","url":"https://stock-news.laohu8.com/highlight/detail?id=2529801578","media":"市场资讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529801578?lang=zh_cn&edition=full","pubTime":"2025-04-21 21:05","pubTimestamp":1745240700,"startTime":"0","endTime":"0","summary":" 突然宣布，或被*ST！ 由于2024年业绩预告由盈利修正为亏损，且扣除非经常损益后营业收入低于3亿元，南华生物或被实施退市风险警示（*ST）。截至2024年三季度末，南华生物的股东人数约为2万户。 4月21日，南华生物股价以9.01元/股报收，最新市值为29.7亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2025-04-21/doc-inetxwtt6119745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0086","BK0042","BK0046","000504","BK0282"],"gpt_icon":0},{"id":"2529387211","title":"南华生物(000504.SZ)：公司股票交易可能被实施退市风险警示","url":"https://stock-news.laohu8.com/highlight/detail?id=2529387211","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529387211?lang=zh_cn&edition=full","pubTime":"2025-04-21 19:15","pubTimestamp":1745234118,"startTime":"0","endTime":"0","summary":"智通财经APP讯，南华生物(000504.SZ)发布公告，公司预计公司2024年度净利润、扣除非经常性损益后的净利润均为负值且扣除后营业收入低于3亿元，根据《深圳证券交易所股票上市规则》第9.3.1条第(一)项规定，在公司2024年年度报告披露后，公司股票交易可能被实施退市风险警示(股票简称前冠以“*ST”字样)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1281629.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000504","BK0046","BK0086","BK0282","BK0042"],"gpt_icon":0},{"id":"2529719318","title":"南华生物最新公告：修正2024年度业绩预告 公司股票可能被实施退市风险警示","url":"https://stock-news.laohu8.com/highlight/detail?id=2529719318","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529719318?lang=zh_cn&edition=full","pubTime":"2025-04-21 18:39","pubTimestamp":1745231992,"startTime":"0","endTime":"0","summary":"南华生物(000504.SZ)发布2024年度业绩预告修正公告，预计净利润为亏损1900万元-2100万元。公司原预计净利润为盈利1250万元–1550万元。公司预计公司2024年度净利润、扣除非经常性损益后的净利润均为负值且扣除后营业收入低于3亿元，根据《深圳证券交易所股票上市规则》第9.3.1条第（一）项规定，在公司2024年年度报告披露后，公司股票交易可能被实施退市风险警示（股票简称前冠以“*ST”字样），敬请广大投资者注意投资风险。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042100024591.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0086","BK0042","BK0282","000504","BK0046"],"gpt_icon":0},{"id":"2529879736","title":"南华生物：修正2024年度业绩预告 公司股票可能被实施退市风险警示","url":"https://stock-news.laohu8.com/highlight/detail?id=2529879736","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529879736?lang=zh_cn&edition=full","pubTime":"2025-04-21 18:38","pubTimestamp":1745231915,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0282","BK0042","000504","BK0086","BK0046","399001"],"gpt_icon":0},{"id":"2505578890","title":"南华生物（000504）1月23日主力资金净卖出286.86万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505578890","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505578890?lang=zh_cn&edition=full","pubTime":"2025-01-23 15:29","pubTimestamp":1737617364,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2025年1月23日收盘，南华生物报收于8.75元，下跌3.1%，换手率1.34%，成交量4.16万手，成交额3741.84万元。南华生物主营业务：主要从事干细胞、免疫细胞等人类生物资源储存、细胞生物技术研发、细胞治疗技术的临床应用研究等细胞医疗服务,同时也是节能环保综合解决方案提供商。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025012300025274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","000504","BK0046","BK0282","BK0086"],"gpt_icon":0},{"id":"2505225190","title":"南华生物(000504.SZ)发预盈，预计2024年度净利润1250万元–1550万元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2505225190","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505225190?lang=zh_cn&edition=full","pubTime":"2025-01-21 19:38","pubTimestamp":1737459515,"startTime":"0","endTime":"0","summary":"智通财经APP讯，南华生物(000504.SZ)发布2024年年度业绩预告，预计全年归属于上市公司股东的净利润1250万元–1550万元，同比扭亏为盈。业绩变动原因：1.报告期内，随着公司资金状况及资本结构的改善，公司财务成本同比上年有较大幅度下降;2.报告期内，通过优化业务管控，公司细胞业务整体盈利能力同比去年有所提升;3.报告期内，公司通过进一步加强自营美妆产品销售、拓展其它产品代理销售等相关领域的衍生业务，增加了收入及利润来源。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1241330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000504"],"gpt_icon":0},{"id":"2505824434","title":"南华生物：预计2024年全年每股收益盈利:0.039元至0.049元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505824434","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505824434?lang=zh_cn&edition=full","pubTime":"2025-01-21 18:03","pubTimestamp":1737453780,"startTime":"0","endTime":"0","summary":"证券之星消息，南华生物发布业绩预告，预计2024年全年每股收益盈利:0.039元至0.049元。南华生物2024年三季报显示，公司主营收入9241.71万元，同比下降11.78%；归母净利润-841.08万元，同比下降1828.05%；扣非净利润-1325.92万元，同比上升14.35%；其中2024年第三季度，公司单季度主营收入3609.23万元，同比上升5.15%；单季度归母净利润-1.79万元，同比下降100.19%；单季度扣非净利润-206.22万元，同比上升55.5%；负债率49.3%，投资收益208.95万元，财务费用-23.45万元，毛利率68.03%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025012100031326.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0086","000504","BK0046","BK0282"],"gpt_icon":0},{"id":"2503564362","title":"异动快报：南华生物（000504）1月14日9点39分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2503564362","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503564362?lang=zh_cn&edition=full","pubTime":"2025-01-14 09:40","pubTimestamp":1736818847,"startTime":"0","endTime":"0","summary":"证券之星1月14日盘中消息，9点39分南华生物触及涨停板。目前价格8.68，上涨10.01%。其所属行业医疗服务目前上涨。该股为干细胞，湖南国企改革，智慧城市概念热股，当日干细胞概念上涨1.63%，湖南国企改革概念上涨1.45%，智慧城市概念上涨0.72%。1月13日的资金流向数据方面，主力资金净流入51.57万元，占总成交额2.79%，游资资金净流出31.73万元，占总成交额1.72%，散户资金净流出19.84万元，占总成交额1.07%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025011400009083.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0086","BK0042","000504","BK0282","BK0046"],"gpt_icon":0},{"id":"2500020151","title":"我国首款干细胞治疗药品上市！概念股名单一览","url":"https://stock-news.laohu8.com/highlight/detail?id=2500020151","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500020151?lang=zh_cn&edition=full","pubTime":"2025-01-03 14:01","pubTimestamp":1735884092,"startTime":"0","endTime":"0","summary":"消息面上，1月2日，国家药监局通过优先审评审批程序附条件批准我国首款干细胞治疗药品艾米迈托赛注射液上市。对此，南财快讯记者以投资者身份就干细胞业务分别致电中源协和、冠昊生物、南华生物，冠昊生物、南华生物工作人员均表示，公司主要涉及干细胞储存，暂无干细胞治疗药品。其中南华生物工作人员称，公司对干细胞治疗有一些研究，但未到临床阶段。文章来源：21世纪经济报道视频丨我国首款干细胞治疗药品上市！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103141914ab9cc7e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103141914ab9cc7e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0086","BK0196","BK0239","600645","BK0183","BK0046","BK0012","300238","000504","BK0251","BK0077","BK0188","BK0216","BK0282","600535","BK0042","BK0028"],"gpt_icon":0},{"id":"2500406132","title":"我国首款干细胞治疗药品上市！多家上市公司回应","url":"https://stock-news.laohu8.com/highlight/detail?id=2500406132","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500406132?lang=zh_cn&edition=full","pubTime":"2025-01-03 11:37","pubTimestamp":1735875447,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0077","BK0239","BK0251","BK0046","BK0282","BK0216","300238","000504","BK0042","BK0086","600645","BK0188"],"gpt_icon":0},{"id":"2500015364","title":"我国首款干细胞治疗药品上市！多家上市公司回应","url":"https://stock-news.laohu8.com/highlight/detail?id=2500015364","media":"21世纪经济报道","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500015364?lang=zh_cn&edition=full","pubTime":"2025-01-03 11:35","pubTimestamp":1735875300,"startTime":"0","endTime":"0","summary":" 1月3日，干细胞概念股开盘异动，中源协和涨7.37%、冠昊生物涨5.15%、南华生物涨3.88%，天士力、我武生物等跟涨。 消息面上，1月2日，国家药监局通过优先审评审批程序附条件批准我国首款干细胞治疗药品艾米迈托赛注射液上市，用于治疗14岁以上消化道受累为主的激素治疗失败的急性移植物抗宿主病。 国盛证券发布的研报显示，截至2024年12月22日，已有数十款干细胞治疗药品进入临床阶段，包括上市的艾米迈托赛。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-01-03/doc-inecseww9575635.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-01-03/doc-inecseww9575635.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600645","600535","BK0188","BK0183","300238","BK0251","BK0196","BK0086","BK0042","BK0028","BK0012","BK0046","BK0216","BK0239","000504","BK0077","BK0282","300357"],"gpt_icon":0},{"id":"2500138895","title":"A股细胞免疫治疗概念股高开，中源协和涨超7%，冠昊生物涨超5%，南华生物、开能健康、阳普医疗等高开。","url":"https://stock-news.laohu8.com/highlight/detail?id=2500138895","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500138895?lang=zh_cn&edition=full","pubTime":"2025-01-03 09:29","pubTimestamp":1735867789,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0135","000504","BK0188","BK0150","BK0239","159982","BK0146","BK0046","BK0042","BK0251","BK0028","300272","BK0086","BK0282","BK0020","06978","600645","BK1161","BK1574","BK0077","BK0224","399300","300238","BK0216","300030"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1746572419845,"stockEarnings":[{"period":"1week","weight":0.049},{"period":"1month","weight":-0.4},{"period":"3month","weight":-0.3355},{"period":"6month","weight":-0.4089},{"period":"1year","weight":-0.2395},{"period":"ytd","weight":-0.2814}],"compareEarnings":[{"period":"1week","weight":0.009},{"period":"1month","weight":-0.0077},{"period":"3month","weight":0.0268},{"period":"6month","weight":-0.0445},{"period":"1year","weight":0.0558},{"period":"ytd","weight":-0.0106}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"南华生物医药股份有限公司","boardCode":"AI0075","boardName":"科技推广和应用服务业","stockholders":"15992人(较上一季度减少5.20%)","perCapita":"19426股","listingDate":"1992-12-08","address":"湖南省长沙市岳麓区高新区岳麓西大道1698号麓谷科技创新创业园B1栋3楼","registeredCapital":"33002万元","survey":" 南华生物医药股份有限公司主要从事“生物医药”和“节能环保”两个板块的业务。公司“生物医药”板块业务包括干细胞和免疫细胞的分离、培养、储存服务及其下游产品和临床应用的研究；公司“节能环保”板块业务包括节能工程及产品研发销售、特种行业污水综合治理、分布式能源站投资经营、综合节能项目投资运营等。","listedPrice":1},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"*ST生物(000504)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供*ST生物(000504)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"*ST生物,000504,*ST生物股票,*ST生物股票老虎,*ST生物股票老虎国际,*ST生物行情,*ST生物股票行情,*ST生物股价,*ST生物股市,*ST生物股票价格,*ST生物股票交易,*ST生物股票购买,*ST生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"*ST生物(000504)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供*ST生物(000504)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}